How should anesthesia be managed in a patient with pseudocholinesterase deficiency?

Anesthesia Management in Pseudocholinesterase Deficiency

Avoid succinylcholine and mivacurium entirely in patients with known pseudocholinesterase deficiency; use rocuronium or benzylisoquinoline muscle relaxants (atracurium/cisatracurium) as safe alternatives for neuromuscular blockade.

Primary Muscle Relaxant Selection

The core issue is that succinylcholine and mivacurium depend on pseudocholinesterase for metabolism, leading to prolonged paralysis and apnea lasting from 10 minutes to 14 hours in deficient patients 1. Multiple recent case reports demonstrate this complication, even in previously undiagnosed individuals 2, 3, 4.

Recommended Alternatives:

For rapid sequence intubation:

• Rocuronium is the preferred alternative to succinylcholine 5
• Use standard intubating doses (0.6-1.2 mg/kg) for rapid onset
• Can be immediately reversed with sugammadex if needed (see reversal section below)
• Low-dose rocuronium has been successfully used in ECT cases after succinylcholine complications 2

For routine cases:

• Atracurium or cisatracurium are excellent choices 6, 3
• These benzylisoquinoline agents undergo organ-independent elimination (Hofmann degradation and ester hydrolysis)
• Do not rely on pseudocholinesterase for metabolism
• Particularly advantageous in patients with concurrent renal or hepatic dysfunction 6

Reversal Strategy

The choice of reversal agent depends on which muscle relaxant you selected:

If using rocuronium or vecuronium:

• Sugammadex is strongly recommended for reversal 6
• Dose according to depth of blockade using quantitative neuromuscular monitoring:
  • Very moderate blockade (TOF ratio 0.5): 0.22 mg/kg
  • Moderate blockade (4 TOF responses): 1.0 mg/kg
  • Moderate blockade (2 TOF responses): 2.0 mg/kg
  • Deep blockade: 4.0 mg/kg
  • Immediate reversal: 8.0 mg/kg 6
• Sugammadex works by encapsulation, not enzymatic breakdown, making it ideal for pseudocholinesterase deficiency

If using atracurium or cisatracurium:

• Neostigmine (0.04 mg/kg) with atropine (0.02 mg/kg) can be used 6
• Only administer when 4 TOF responses are present
• Wait 10-20 minutes for full reversal (TOF ratio ≥0.9)
• Continue quantitative neuromuscular monitoring throughout

Critical Monitoring Requirements

Quantitative neuromuscular monitoring is mandatory throughout the case 6:

• Use train-of-four (TOF) stimulation at the adductor pollicis
• Visual or tactile assessment is insufficient for safe management
• Monitor continuously until TOF ratio ≥0.9 is achieved
• Post-tetanic count (PTC) may be needed for deep blockade assessment

Common Pitfalls to Avoid

1. Never assume normal recovery time: Even with alternative agents, individual variability exists. Always monitor objectively.

2. Drug interactions: Cholinesterase inhibitors (rivastigmine, donepezil, pyridostigmine) can unmask or worsen pseudocholinesterase deficiency 2. Review medication lists carefully.

3. Acquired deficiency: Pregnancy, liver disease, malnutrition, burns, and certain medications can cause acquired pseudocholinesterase deficiency 1. Consider these risk factors even without genetic confirmation.

4. ECT considerations: This population frequently requires ECT. Rocuronium or atracurium are safe alternatives that allow continuation of treatment 2, 3, 4.

5. Ambulatory surgery settings: Ensure adequate resources for prolonged ventilatory support if complications occur, as outpatient facilities may have limited capabilities 1.

If Succinylcholine Already Administered

If prolonged paralysis occurs after inadvertent succinylcholine use:

• Maintain mechanical ventilation until spontaneous recovery occurs (this is the only treatment) 1
• Provide adequate sedation to prevent awareness and psychological trauma 7
• Duration can extend up to 14 hours; patience is required
• All reported cases made full recovery with supportive care 1
• Confirm diagnosis post-operatively with serum cholinesterase levels and genetic testing 3, 7

Family Counseling

Pseudocholinesterase deficiency is inherited (autosomal recessive pattern from BCHE gene mutations) 5, 7. Recommend:

• Genetic counseling for the patient and family members
• Medical alert identification (bracelet/card)
• Preemptive BCHE genetic testing for at-risk relatives to prevent future complications 7